Advertisement
CRL vs MEDP
Which Stock Would AI Choose? Charles River Laboratories (CRL) vs. Medpace Holdings (MEDP) Stock Comparison
Key Takeaways
- Both CRL and MEDP operate as contract research organizations (CROs) serving the pharmaceutical and biotechnology industries, exposing them to similar cyclical demand tied to drug development pipelines.
- Recent market activity shows CRL experiencing more pronounced volatility linked to broader biotech funding trends, while MEDP has demonstrated relatively steadier momentum in comparable periods.
- Sector exposure for both centers on life sciences services, with growth drivers including clinical trial outsourcing and regulatory support services amid evolving drug approval landscapes.
- Risk factors for each include sensitivity to client spending patterns, potential margin pressures from operational scaling, and macroeconomic influences on research and development budgets.
- Market sentiment has reflected cautious optimism for the CRO sector overall, with relative performance hinging on execution of backlog conversion and client retention metrics.
- Comparative positioning highlights trade-offs between CRL’s broader service portfolio and MEDP’s specialized focus on certain therapeutic areas.
Introduction
Charles River Laboratories (CRL) and Medpace Holdings (MEDP) represent two prominent players in the contract research organization (CRO) space, making them natural subjects for comparison among investors tracking healthcare services and life sciences outsourcing. Traders and portfolio managers seeking exposure to drug development cycles often evaluate these names alongside broader market benchmarks to assess relative value and sector momentum. This analysis examines their business models, recent performance patterns, and positioning within the current market environment, providing context for those considering allocation decisions in the healthcare services segment.
CRL Overview and Recent Performance
Charles River Laboratories provides essential research models, preclinical services, and clinical support to pharmaceutical, biotechnology, and academic clients worldwide. In recent weeks, the stock has reflected the mixed environment for life sciences outsourcing, with price movements influenced by fluctuations in biotech funding availability and trial initiation rates. Market activity has highlighted the company’s exposure to early-stage discovery work, which tends to amplify sensitivity to capital markets conditions affecting smaller clients. Sentiment has been shaped by ongoing integration of acquired capabilities and efforts to expand capacity in high-demand therapeutic areas, contributing to a measured response in share price relative to sector peers.
MEDP Overview and Recent Performance
Medpace Holdings specializes in full-service clinical development, offering regulatory, medical, and operational expertise primarily for Phase I through IV trials across multiple therapeutic categories. Recent market activity has shown the stock maintaining a more consistent trajectory amid sector headwinds, supported by strong backlog visibility and client diversification. Performance patterns reflect the benefits of its focused operational model, which emphasizes therapeutic expertise and efficient trial execution. Sentiment has remained supported by steady conversion of existing contracts and expansion into emerging modalities, positioning the company favorably within the broader CRO competitive landscape.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of the platform’s AI trading bots. Tickeron offers hundreds of AI Trading Bots that trade thousands of different tickers, yet only the strongest performers suited to prevailing market conditions earn placement in this Trending section. Available bots span a wide range of trading styles, strategies, timeframes, and performance statistics, with many demonstrating win rates between 55% and 75% alongside varying profit factors and drawdown profiles across different market regimes. Readers interested in exploring automated strategies tailored to specific tickers or market environments can review the full collection on the Trending AI Robots page.
Head-to-Head Comparison
Both companies function as contract research organizations (CROs), yet they differ in service breadth and client focus. CRL offers an integrated suite spanning discovery through early clinical stages, providing wider revenue diversification but greater exposure to preclinical spending cycles. MEDP concentrates on later-stage clinical execution with deep therapeutic specialization, which can support more predictable backlog conversion. Recent momentum has favored steadier performers in the segment, with MEDP showing relatively resilient price behavior compared with the more variable path observed for CRL. Risk considerations include shared sensitivity to research and development budget shifts, though CRL’s larger scale introduces different operational leverage dynamics. Sector exposure remains aligned with pharmaceutical outsourcing trends, while market sentiment continues to weigh execution metrics and funding environment signals for both names.
Tickeron AI Verdict
Based on observable factors such as trend consistency and relative positioning in recent market activity, Tickeron’s AI models currently assign a modestly higher probability of favorable near-term behavior to MEDP over CRL, driven by steadier momentum patterns and backlog visibility. This assessment remains probabilistic and subject to shifts in sector catalysts or broader market conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRL is a Hold and MEDP is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CRL’s FA Score shows that 2 FA rating(s) are green whileMEDP’s FA Score has 2 green FA rating(s).
- CRL’s FA Score: 2 green, 3 red.
- MEDP’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CRL’s TA Score shows that 5 TA indicator(s) are bullish while MEDP’s TA Score has 5 bullish TA indicator(s).
- CRL’s TA Score: 5 bullish, 4 bearish.
- MEDP’s TA Score: 5 bullish, 3 bearish.
Price Growth
CRL (@Medical Specialties) experienced а +0.99% price change this week, while MEDP (@Medical Specialties) price change was +11.84% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.55%. For the same industry, the average monthly price growth was +2.80%, and the average quarterly price growth was +1.12%.
Reported Earning Dates
CRL is expected to report earnings on Aug 12, 2026.
MEDP is expected to report earnings on Oct 26, 2026.
Industries' Descriptions
@Medical Specialties (-1.55% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| CRL | MEDP | CRL / MEDP | |
| Capitalization | 10.9B | 16.8B | 65% |
| EBITDA | 291M | 591M | 49% |
| Gain YTD | 13.585 | 7.074 | 192% |
| P/E Ratio | 577.05 | 35.33 | 1,633% |
| Revenue | 4.03B | 2.68B | 150% |
| Total Cash | 192M | 653M | 29% |
| Total Debt | 3.06B | 122M | 2,505% |
CRL | MEDP | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 81 | 86 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 89 Overvalued | 80 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 26 | |
SMR RATING 1..100 | 94 | 15 | |
PRICE GROWTH RATING 1..100 | 6 | 37 | |
P/E GROWTH RATING 1..100 | 2 | 41 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MEDP's Valuation (80) in the Miscellaneous Commercial Services industry is in the same range as CRL (89). This means that MEDP’s stock grew similarly to CRL’s over the last 12 months.
MEDP's Profit vs Risk Rating (26) in the Miscellaneous Commercial Services industry is significantly better than the same rating for CRL (100). This means that MEDP’s stock grew significantly faster than CRL’s over the last 12 months.
MEDP's SMR Rating (15) in the Miscellaneous Commercial Services industry is significantly better than the same rating for CRL (94). This means that MEDP’s stock grew significantly faster than CRL’s over the last 12 months.
CRL's Price Growth Rating (6) in the Miscellaneous Commercial Services industry is in the same range as MEDP (37). This means that CRL’s stock grew similarly to MEDP’s over the last 12 months.
CRL's P/E Growth Rating (2) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for MEDP (41). This means that CRL’s stock grew somewhat faster than MEDP’s over the last 12 months.
| CRL | MEDP | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 77% | 2 days ago 86% |
| Stochastic ODDS (%) | 2 days ago 68% | 2 days ago 80% |
| Momentum ODDS (%) | 2 days ago 77% | 2 days ago 75% |
| MACD ODDS (%) | 2 days ago 83% | 2 days ago 83% |
| TrendWeek ODDS (%) | 2 days ago 67% | 2 days ago 76% |
| TrendMonth ODDS (%) | 2 days ago 64% | 2 days ago 76% |
| Advances ODDS (%) | 20 days ago 69% | 16 days ago 76% |
| Declines ODDS (%) | 4 days ago 72% | 6 days ago 63% |
| BollingerBands ODDS (%) | 2 days ago 74% | 2 days ago 76% |
| Aroon ODDS (%) | 2 days ago 61% | 2 days ago 76% |
Advertisement
MEDP and
Correlation & Price change
A.I.dvisor indicates that over the last year, MEDP has been loosely correlated with CRL. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MEDP jumps, then CRL could also see price increases.
| Ticker / NAME | Correlation To MEDP | 1D Price Change % | ||
|---|---|---|---|---|
| MEDP | 100% | -0.73% | ||
| CRL - MEDP | 53% Loosely correlated | -1.18% | ||
| TMO - MEDP | 47% Loosely correlated | -0.71% | ||
| BRKR - MEDP | 43% Loosely correlated | -2.74% | ||
| RVTY - MEDP | 39% Loosely correlated | -2.39% | ||
| ICLR - MEDP | 39% Loosely correlated | -2.68% | ||
More | ||||